Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Rivian Automotive Whale Trades For May 13

Someone with a lot of money to spend has taken a bearish stance on Rivian Automotive (NASDAQ:RIVN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Looking At Starbucks's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Starbucks (NASDAQ:SBUX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences

RBC Capital writes that Wave Life Sciences Ltd's (NASDAQ: WVE) Q1 earnings are largely incremental.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Legacy Housing Appoints Ronald Arrington As Finance Head

Legacy Housing Corp (NASDAQ:LEGH) has appointed Ronald Arrington as Chief Financial Officer (CFO). He will replace Jeff Burt, who served as Interim CFO of Legacy, and will remain as the Chief Accounting Officer. Related: Legacy Housing CFO Thomas Kerkaert Resigns Arrington has served as CFO and in other executive positions for construction, retail, and…

Benzinga

Why Real Good Food Shares Are Gaining Today

Real Good Food Company Inc (NASDAQ:RGF) reported first-quarter FY22 sales growth of 124% year-on-year to $37.58 million, beating the consensus of $32.47 million. The revenue increase was driven by strong growth in sales volumes of core products. The gross profit increased 5.8% Y/Y to $4.2 million, and the gross margin contracted 1,260 basis…

Benzinga

Analysts Share Their Views On Affirm Post Q3 Beat

Analysts offered a mixed opinion on Affirm Holdings, Inc (NASDAQ: AFRM)

Benzinga

Here's Why This Analyst Remained Bullish On Microsoft

Tigress Financial Partners analyst Ivan Feinseth reiterated its Buy rating on Microsoft Corp (NASDAQ:MSFT) and maintained the price target of $411 as growth in Cloud continues to drive strong business performance. The recent pullback in price is a significant buying opportunity. Accelerating enterprise digitalization driving increasing IT spending will continue to drive accelerating Business Performance…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition

InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the fiscal year 2022 which ended March 31, 2022.

Benzinga

Biden Says US Ready To Share COVID-19 Vaccine Related Technology

President Joe Biden said that the U.S. will share technologies used to make COVID-19 vaccines through the World Health Organization and is working on expanding rapid testing and antiviral treatments for hard-to-reach populations. "We are making available health technologies that are owned by the United States government, including stabilized spike protein that…

Benzinga

What 4 Analyst Ratings Have To Say About Snap One Holdings

Within the last quarter, Snap One Holdings (NASDAQ:SNPO) has observed the following analyst ratings:

Benzinga

Analyst Ratings for Cytek Biosciences

Over the past 3 months, 4 analysts have published their opinion on Cytek Biosciences (NASDAQ:CTKB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Expert Ratings for Expensify

Expensify (NASDAQ:EXFY) has observed the following analyst ratings within the last quarter:

Benzinga

Looking Into Wynn Resorts's Recent Short Interest

Wynn Resorts's (NASDAQ:WYNN) short percent of float has risen 15.34% since its last report. The company recently reported that it has 5.96 million shares sold short, which is 5.64% of all regular shares that are available for trading.

Benzinga

Where Indie Semiconductor Stands With Analysts

Within the last quarter, Indie Semiconductor (NASDAQ:INDI) has observed the following analyst ratings:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

10 Information Technology Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Benzinga

10 Consumer Discretionary Stocks With Whale Alerts In Today's Session

Benzinga

10 Communication Services Stocks Whale Activity In Today's Session

Benzinga

11 Industrials Stocks Moving In Friday's Intraday Session

Gainers

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Read Why Did Raymond James Slash Price Target On Inflarx

Raymond James remains a Strong Buy on Inflarx NV (NASDAQ: IFRX) following 1Q22 earnings based on a promising outlook for vilobelimab in Pyoderma Gangrenosum (PG) and potentially other indications. The biotech macro backdrop has forced many companies to be prudent with cash runway and prioritize clinical programs. InflaRx is also focusing on a potential pivotal trial…

Benzinga

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

Benzinga

Mizuho Remains Bullish On This Small-Cap Stock's Migraine Candidate, But Why Did It Cut Price Target

Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal dihydroergotamine (DHE) for migraine.

Benzinga

Why This Old National Bancorp Analyst Is Turning Bullish

Cost savings from Old National Bancorp’s (NASDAQ: ONB) deal to merge with First Midwest Bancorp should be accretive to the bottom line “following the systems conversion in July,” according to Stephens.

Benzinga

Earnings Preview: Dada Nexus

Dada Nexus (NASDAQ:DADA) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Dada Nexus will report an earnings per share (EPS) of $-0.24.

Benzinga

Expert Ratings for Vor Biopharma

Analysts have provided the following ratings for Vor Biopharma (NASDAQ:VOR) within the last quarter:

Benzinga

A Preview Of HyreCar's Earnings

HyreCar (NASDAQ:HYRE) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that HyreCar will report an earnings per share (EPS) of $-0.24.

1 … 492 493 494 495

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.